BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11695557)

  • 1. Panel discussion on the application of alternative models to cancer risk assessment.
    Pettit SD
    Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
    Robinson DE; MacDonald JS
    Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of human cancer risk: challenges for alternative approaches.
    Omenn GS
    Toxicol Pathol; 2001; 29 Suppl():5-12. PubMed ID: 11695561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CB6F1-rasH2 mouse: overview of available data.
    Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
    Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highlights of International meeting on Alternative Methods of Carcinogenicity Testing, Leesburg, VA, November 1-3, 2000, Sponsored by the Health and Environmental Sciences Institute.
    Jollow DJ
    J Agromedicine; 2004; 9(2):427-9. PubMed ID: 19785235
    [No Abstract]   [Full Text] [Related]  

  • 8. Expectations for transgenic rodent cancer bioassay models.
    Ashby J
    Toxicol Pathol; 2001; 29 Suppl():177-82. PubMed ID: 11695555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and theEnvironment. Statement on ILSI/HESI research programme on alternative cancer models.
    Blain PG
    Toxicol Pathol; 2003; 31(2):254-7. PubMed ID: 12696588
    [No Abstract]   [Full Text] [Related]  

  • 10. Xpa and Xpa/p53+/- knockout mice: overview of available data.
    van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
    Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria for the evaluation of studies in transgenic models.
    Popp JA
    Toxicol Pathol; 2001; 29 Suppl():20-3. PubMed ID: 11695558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of the uses of rats and mice for assessing carcinogenic risk from chemicals in humans.
    Ward JM
    Asian Pac J Cancer Prev; 2010; 11(1):18. PubMed ID: 20593921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53+/- hemizygous knockout mouse: overview of available data.
    Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
    Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
    MacDonald J; French JE; Gerson RJ; Goodman J; Inoue T; Jacobs A; Kasper P; Keller D; Lavin A; Long G; McCullough B; Sistare FD; Storer R; van der Laan JW
    Toxicol Sci; 2004 Feb; 77(2):188-94. PubMed ID: 14657512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The International Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk.
    Robinson D
    Toxicol Pathol; 1998; 26(4):474-5. PubMed ID: 9715505
    [No Abstract]   [Full Text] [Related]  

  • 16. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
    Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
    Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of transgenic mice in carcinogenicity hazard assessment.
    Jacobson-Kram D; Sistare FD; Jacobs AC
    Toxicol Pathol; 2004; 32 Suppl 1():49-52. PubMed ID: 15209403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal mouse model: review of methods and results.
    McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
    Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically altered mouse models for identifying carcinogens.
    Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
    IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.